BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-757, e350. [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Savarino E, Zentilin P, Savarino V. It is time to plan clinical trials on true NERD patients. Neurogastroenterol Motil 2012;24:885-6; author reply 887. [PMID: 22908863 DOI: 10.1111/j.1365-2982.2012.01964.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Nennstiel S, Bajbouj M, Schmid RM, Becker V. Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series. J Med Case Rep. 2014;8:34. [PMID: 24502186 DOI: 10.1186/1752-1947-8-34] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
3 Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0586-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
4 Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. Gastroenterology. 2016;150:1368-1379. [PMID: 27144625 DOI: 10.1053/j.gastro.2016.02.012] [Cited by in Crossref: 254] [Cited by in F6Publishing: 133] [Article Influence: 42.3] [Reference Citation Analysis]
5 Marks SL, Kook PH, Papich MG, Tolbert MK, Willard MD. ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. J Vet Intern Med 2018;32:1823-40. [PMID: 30378711 DOI: 10.1111/jvim.15337] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
6 Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther 2021;15:1609-21. [PMID: 33907381 DOI: 10.2147/DDDT.S306371] [Reference Citation Analysis]
7 Alhossan A, Alrabiah Z, Alghadeer S, Bablghaith S, Wajid S, Al-Arifi M. Attitude and knowledge of Saudi community pharmacists towards use of proton pump inhibitors. Saudi Pharm J 2019;27:225-8. [PMID: 30766433 DOI: 10.1016/j.jsps.2018.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gyawali CP. Redeeming Clinical Value of Esophageal pH Impedance Monitoring. Clin Gastroenterol Hepatol 2016;14:47-9. [PMID: 26325401 DOI: 10.1016/j.cgh.2015.08.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ribolsi M, Giordano A, Guarino MPL, Tullio A, Cicala M. New classifications of gastroesophageal reflux disease: an improvement for patient management? Expert Review of Gastroenterology & Hepatology 2019;13:761-9. [DOI: 10.1080/17474124.2019.1645596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 de Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E, Ceccarelli L, Stasi C, Bellini M, Savarino V, Savarino EV, Marchi S. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018;31:639-48. [PMID: 30386113 DOI: 10.20524/aog.2018.0314] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
11 Savarino E, Zentilin P, Marabotto E, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18:1333-1343. [PMID: 28754071 DOI: 10.1080/14656566.2017.1361407] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
12 Woodland P, Batista-lima F, Lee C, Preston SL, Dettmar P, Sifrim D. Topical protection of human esophageal mucosal integrity. American Journal of Physiology-Gastrointestinal and Liver Physiology 2015;308:G975-80. [DOI: 10.1152/ajpgi.00424.2014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
13 Savarino V, Pace F, Scarpignato C; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther 2017;45:631-42. [PMID: 28116754 DOI: 10.1111/apt.13914] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
14 Funaki Y, Kaneko H, Kawamura Y, Yoshimine T, Tamura Y, Izawa S, Ebi M, Ogasawara N, Sasaki M, Kasugai K. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan. Digestion 2017;96:39-45. [PMID: 28641289 DOI: 10.1159/000477801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 Bortoli N, Gyawali CP, Frazzoni M, Tolone S, Frazzoni L, Vichi E, Visaggi P, Bellini M, Marabotto E, Penagini R, Savarino V, Marchi S, Savarino EV. Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. Neurogastroenterology & Motility 2020;32. [DOI: 10.1111/nmo.13919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Nagahara A, Hojo M, Asaoka D, Sasaki H, Watanabe S. A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scand J Gastroenterol 2014;49:409-17. [PMID: 24444414 DOI: 10.3109/00365521.2013.878380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
17 Kandulski A, Jechorek D, Caro C, Weigt J, Wex T, Mönkemüller K, Malfertheiner P. Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn. Aliment Pharmacol Ther 2013;38:643-51. [PMID: 23895770 DOI: 10.1111/apt.12428] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
18 Kandulski A, Peitz U, Mönkemüller K, Neumann H, Weigt J, Malfertheiner P. GERD assessment including pH metry predicts a high response rate to PPI standard therapy. BMC Gastroenterol 2013;13:12. [PMID: 23324360 DOI: 10.1186/1471-230X-13-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
19 Cho YK, Choi MG, Park H, Kim JW, Lee DH, Ko KH, Kim SG, Jung HY, Hong SJ, Lee YC, Lee SH. Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial. J Neurogastroenterol Motil 2021;27:223-30. [PMID: 33795542 DOI: 10.5056/jnm19053] [Reference Citation Analysis]
20 Calabrese C, Salice M. Revenge of the NERDs: Cadherin Fragments Differentiate Functional Heartburn from Non-erosive Reflux Disease. Dig Dis Sci 2018;63:547-8. [PMID: 29330729 DOI: 10.1007/s10620-017-4872-8] [Reference Citation Analysis]
21 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
22 Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, Chen MH, Choi MG, Melo AC, Fock KM, Ford A, Hongo M, Khan A, Lazebnik L, Lindberg G, Lizarzabal M, Myint T, Moraes-Filho JP, Salis G, Lin JT, Vaidya R, Abdo A, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51:467-478. [PMID: 28591069 DOI: 10.1097/mcg.0000000000000854] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 18.7] [Reference Citation Analysis]
23 Naik RD, Vaezi MF. Extra-esophageal gastroesophageal reflux disease and asthma: understanding this interplay. Expert Rev Gastroenterol Hepatol. 2015;9:969-982. [PMID: 26067887 DOI: 10.1586/17474124.2015.1042861] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
24 Smout AJ, Bredenoord AJ. GERD: A challenge to our view of reflux oesophagitis pathogenesis. Nat Rev Gastroenterol Hepatol 2016;13:504-5. [PMID: 27407046 DOI: 10.1038/nrgastro.2016.106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Kusano M, Hosaka H, Kawamura O, Kawada A, Kuribayashi S, Shimoyama Y, Yasuoka H, Mizuide M, Tomizawa T, Sagawa T, Sato K, Yamada M. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. J Gastroenterol 2015;50:298-304. [PMID: 24919745 DOI: 10.1007/s00535-014-0972-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkkilä M, Lynge E, Pukkala E, Romundstad P, Tryggvadóttir L, -Chelpin MVE, Lagergren J. Survival after antireflux surgery versus medication in patients with reflux oesophagitis or Barrett's oesophagus: multinational cohort study. Br J Surg 2021;108:864-70. [PMID: 33724340 DOI: 10.1093/bjs/znab024] [Reference Citation Analysis]
27 Estores DS. Symptom Predictability in Gastroesophageal Reflux Disease and Role of Proton Pump Inhibitor Test. Gastroenterology Clinics of North America 2014;43:27-38. [DOI: 10.1016/j.gtc.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24:697-704. [PMID: 22783985 DOI: 10.1111/j.1365-2982.2012.01977.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
29 Rodríguez de Santiago E, Albéniz E, Estremera-Arevalo F, Teruel Sanchez-Vegazo C, Lorenzo-Zúñiga V. Endoscopic anti-reflux therapy for gastroesophageal reflux disease. World J Gastroenterol 2021; 27(39): 6601-6614 [PMID: 34754155 DOI: 10.3748/wjg.v27.i39.6601] [Reference Citation Analysis]
30 Nicolau LA, Batista-lima FJ, Santana AP, Sales TM, Carmo-neto JP, Freitas GB, Oliveira TM, Medeiros JV, Silva DA, Lee C, Woodland PJ, Soares PM, Vale ML, Santos AA, Sifrim D, Souza MH. Cashew gum, a biopolymer, topically protects oesophageal mucosa in non erosive reflux disease: A promising translational study. Carbohydrate Polymers 2019;226:115205. [DOI: 10.1016/j.carbpol.2019.115205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Fox MR, Kahrilas PJ, Roman S, Gyawali CP, Scott SM, Rao SS, Keller J, Camilleri M; International Working Group for Disorders of Gastrointestinal Motility and Function. Clinical measurement of gastrointestinal motility and function: who, when and which test? Nat Rev Gastroenterol Hepatol 2018;15:568-79. [PMID: 29872118 DOI: 10.1038/s41575-018-0030-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
32 Frazzoni L, Frazzoni M, de Bortoli N, Tolone S, Martinucci I, Fuccio L, Savarino V, Savarino E. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol 2018;31:1-7. [PMID: 29333061 DOI: 10.20524/aog.2017.0199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
33 López-Colombo A, Pacio-Quiterio MS, Jesús-Mejenes LY, Rodríguez-Aguilar JE, López-Guevara M, Montiel-Jarquín AJ, López-Alvarenga JC, Morales-Hernández ER, Ortiz-Juárez VR, Ávila-Jiménez L. Risk factors associated with gastroesophageal reflux disease relapse in primary care patients successfully treated with a proton pump inhibitor. Rev Gastroenterol Mex 2017;82:106-14. [PMID: 28283313 DOI: 10.1016/j.rgmx.2016.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26:28-35. [PMID: 23992024 DOI: 10.1111/nmo.12221] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
35 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
36 Niu XP, Yu BP, Wang YD, Han Z, Liu SF, He CY, Zhang GZ, Wu WC. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol 2013; 19(20): 3124-3129 [PMID: 23716993 DOI: 10.3748/wjg.v19.i20.3124] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
37 Majewski M, Sarosiek I, Cooper CJ, Wallner G, McCallum RW, Edlavitch SA, Sarosiek J. Gastric pH and Therapeutic Responses to Exsomeprazole in Patients With Functional Dyspepsia: Potential Clinical Implications. Am J Med Sci 2016;352:582-92. [PMID: 27916213 DOI: 10.1016/j.amjms.2016.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Savarino E, De Cassan C, Bodini G, Furnari M, de Bortoli N, Savarino V. The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. J Gastroenterol 2014;49:1362-3. [PMID: 24972668 DOI: 10.1007/s00535-014-0974-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet. 2013;381:1933-1942. [PMID: 23477993 DOI: 10.1016/s0140-6736(12)62171-0] [Cited by in Crossref: 93] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
40 de Bortoli N, Ottonello A, Zerbib F, Sifrim D, Gyawali CP, Savarino E. Between GERD and NERD: the relevance of weakly acidic reflux: Weakly acidic reflux in GERD. Ann N Y Acad Sci 2016;1380:218-29. [DOI: 10.1111/nyas.13169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
41 Xie C, Sifrim D, Li Y, Chen M, Xiao Y. Esophageal Baseline Impedance Reflects Mucosal Integrity and Predicts Symptomatic Outcome With Proton Pump Inhibitor Treatment. J Neurogastroenterol Motil 2018;24:43-50. [PMID: 29156514 DOI: 10.5056/jnm17032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
42 Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013;10:371-80. [DOI: 10.1038/nrgastro.2013.50] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 13.6] [Reference Citation Analysis]
43 Yang JH, Kang HS, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ. Recurrence of gastroesophageal reflux disease correlated with a short dinner-to-bedtime interval. J Gastroenterol Hepatol. 2014;29:730-735. [PMID: 24224689 DOI: 10.1111/jgh.12455] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
44 Weijenborg PW, Smout AJ, Bredenoord AJ. Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn. Neurogastroenterol Motil 2016;28:1649-54. [PMID: 27194216 DOI: 10.1111/nmo.12864] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
45 Suzuki T, Matsushima M, Masui A, Tsuda S, Imai J, Nakamura J, Tsukune Y, Uchida T, Yuhara H, Igarashi M, Koike J, Mine T. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study. World J Gastroenterol 2015; 21(16): 5023-5031 [PMID: 25945018 DOI: 10.3748/wjg.v21.i16.5023] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
46 Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J. Nonerosive reflux disease: clinical concepts. Ann N Y Acad Sci 2018;1434:290-303. [DOI: 10.1111/nyas.13845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
47 Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, Ai MH, Wang J, Lv XG, Yang ZR, Dong WG. Proton pump inhibitor for non-erosive reflux disease: A meta-analysis. World J Gastroenterol 2013; 19(45): 8408-8419 [PMID: 24363534 DOI: 10.3748/wjg.v19.i45.8408] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
48 Ostovaneh MR, Saeidi B, Hajifathalian K, Farrokhi-Khajeh-Pasha Y, Fotouhi A, Mirbagheri SS, Emami H, Barzin G, Mirbagheri SA. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil. 2014;26:670-678. [PMID: 24533896 DOI: 10.1111/nmo.12313] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
49 Erridge S, Moussa OM, Ziprin P, Darzi A, Purkayastha S. Risk of GERD-Related Disorders in Obese Patients on PPI Therapy: a Population Analysis. Obes Surg 2018;28:2796-803. [PMID: 29717405 DOI: 10.1007/s11695-018-3246-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Liu G, Jiang C, Li D, Yao L, Lin Y, Wang B, Qiu J, Wang W, Wang W. Isorhamnetin alleviates esophageal mucosal injury in a chronic model of reflux esophagitis. European Journal of Pharmacology 2019;864:172720. [DOI: 10.1016/j.ejphar.2019.172720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Cicala M, Emerenziani S, Guarino MPL, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19(39): 6529-6535 [PMID: 24151377 DOI: 10.3748/wjg.v19.i39.6529] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
52 Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38:190-201. [PMID: 23718547 DOI: 10.1111/apt.12349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
53 Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Pauwels A, Boecxstaens V, Andrews CN, Attwood SE, Berrisford R, Bisschops R, Boeckxstaens GE, Bor S, Bredenoord AJ, Cicala M, Corsetti M, Fornari F, Gyawali CP, Hatlebakk J, Johnson SB, Lerut T, Lundell L, Mattioli S, Miwa H, Nafteux P, Omari T, Pandolfino J, Penagini R, Rice TW, Roelandt P, Rommel N, Savarino V, Sifrim D, Suzuki H, Tutuian R, Vanuytsel T, Vela MF, Watson DI, Zerbib F, Tack J. How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut. 2019;68:1928-1941. [PMID: 31375601 DOI: 10.1136/gutjnl-2019-318260] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
55 Patel A, Sayuk GS, Gyawali CP. Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring. Neurogastroenterol Motil 2016;28:1382-90. [PMID: 27061427 DOI: 10.1111/nmo.12838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
56 Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154:302-318. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 109] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
57 Silva RO, Oliveira FFB, Bingana RD, Arruda MO, Woodland P, Lee C, Souza MAN, Soares PMG, Santos AA, Sifrim D, Souza MHLP. A novel murine model of esophageal nonerosive reflux disease: from inflammation to impairment in mucosal integrity. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017;312:G658-65. [DOI: 10.1152/ajpgi.00327.2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
58 Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, Ahuja V, Rao GV, Devadas K, Dutta AK, Jain A, Kedia S, Dama R, Kalapala R, Alvares JF, Dadhich S, Dixit VK, Goenka MK, Goswami BD, Issar SK, Leelakrishnan V, Mallath MK, Mathew P, Mathew P, Nandwani S, Pai CG, Peter L, Prasad AVS, Singh D, Sodhi JS, Sud R, Venkataraman J, Midha V, Bapaye A, Dutta U, Jain AK, Kochhar R, Puri AS, Singh SP, Shimpi L, Sood A, Wadhwa RT. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-40. [PMID: 31802441 DOI: 10.1007/s12664-019-00979-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
59 Zhang M, Chen M, Peng S, Xiao Y. The Rome IV versus Rome III criteria for heartburn diagnosis: A comparative study. United European Gastroenterol J 2018;6:358-66. [PMID: 29774149 DOI: 10.1177/2050640617735084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
60 Bredenoord AJ, Smout AJPM. Association between reflux and symptoms during ambulatory reflux monitoring: pros and cons of existing methods. Neurogastroenterol Motil 2013;25:633-7. [DOI: 10.1111/nmo.12164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
61 Galmiche JP, Zerbib F, des Varannes SB. Treatment of GORD: Three decades of progress and disappointments. United European Gastroenterol J 2013;1:140-50. [PMID: 24917952 DOI: 10.1177/2050640613484021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
62 Nikaki K, Woodland P, Sifrim D. Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments. Nat Rev Gastroenterol Hepatol. 2016;13:529-542. [PMID: 27485786 DOI: 10.1038/nrgastro.2016.109] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
63 Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice AH, Dettmar PW, editors. Reflux Aspiration and Lung Disease. Cham: Springer International Publishing; 2018. pp. 269-91. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Kim JY, Kim N, Seo PJ, Lee JW, Kim MS, Kim SE, Jo SY, Lee DH, Jung HC. Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea. J Neurogastroenterol Motil. 2013;19:344-354. [PMID: 23875102 DOI: 10.5056/jnm.2013.19.3.344] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
65 Becker V, Grotz S, Schlag C, Nennstiel S, Beitz A, Haller B, Schmid RM, Meining A, Bajbouj M. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol 2014; 20(14): 4017-4024 [PMID: 24744591 DOI: 10.3748/wjg.v20.i14.4017] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
66 Gawron AJ, Pandolfino JE, Miskevics S, Lavela SL. Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease. J Gen Intern Med 2013;28:930-7. [PMID: 23400526 DOI: 10.1007/s11606-013-2345-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
67 Savarino V, Marabotto E, Zentilin P, Demarzo MG, Pellegatta G, Frazzoni M, De Bortoli N, Tolone S, Giannini EG, Savarino E. Esophageal reflux hypersensitivity: Non-GERD or still GERD? Dig Liver Dis 2020;52:1413-20. [PMID: 33097427 DOI: 10.1016/j.dld.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Woodland P, Sifrim D. Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors. Curr Opin Gastroenterol. 2013;29:431-436. [PMID: 23549342 DOI: 10.1097/mog.0b013e328360433c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
69 Hungin APS, Molloy-Bland M, Scarpignato C. Revisiting Montreal: New Insights into Symptoms and Their Causes, and Implications for the Future of GERD. Am J Gastroenterol 2019;114:414-21. [PMID: 30323266 DOI: 10.1038/s41395-018-0287-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
70 Herregods TV, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJ. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27:1267-1273. [PMID: 26088946 DOI: 10.1111/nmo.12620] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
71 de Bortoli N, Martinucci I, Bertani L, Russo S, Franchi R, Furnari M, Tolone S, Bodini G, Bolognesi V, Bellini M, Savarino V, Marchi S, Savarino EV. Esophageal testing: What we have so far. World J Gastrointest Pathophysiol 2016; 7(1): 72-85 [PMID: 26909230 DOI: 10.4291/wjgp.v7.i1.72] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
72 Parasa S, Sharma P. Complications of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2013;27:433-442. [PMID: 23998980 DOI: 10.1016/j.bpg.2013.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
73 Cremonini F. Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil. 2014;26:893-900. [PMID: 24965903 DOI: 10.1111/nmo.12384] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
74 Woodland P, Sifrim D. Oesophageal mucosal barrier: a key factor in the pathophysiology of non-erosive reflux disease (NERD) and a potential target for treatment. Gut 2014;63:705-6. [DOI: 10.1136/gutjnl-2013-305101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
75 Luo X, Guo XX, Wang WF, Peng LH, Yang YS, Uedo N. Autofluorescence imaging endoscopy can distinguish non-erosive reflux disease from functional heartburn: A pilot study. World J Gastroenterol 2016; 22(14): 3845-3851 [PMID: 27076770 DOI: 10.3748/wjg.v22.i14.3845] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kandulski A, Malfertheiner P. Helicobacter pylori and gastroesophageal reflux disease: . Current Opinion in Gastroenterology 2014;30:402-7. [DOI: 10.1097/mog.0000000000000085] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
77 Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet. Clin Gastroenterol Hepatol 2020;18:767-76. [PMID: 31319183 DOI: 10.1016/j.cgh.2019.07.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
78 Azzam RS. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS? Arq Gastroenterol 2018;55Suppl 1:85-91. [PMID: 30304291 DOI: 10.1590/S0004-2803.201800000-48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
79 Chen GW, Xie S, Lian YH, Chen JK. Psychological intervention for auxiliary treatment of non-erosive reflux disease. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4375-4380 [DOI: 10.11569/wcjd.v24.i32.4375] [Reference Citation Analysis]
80 Tack J, Zerbib F, Blondeau K, des Varannes SB, Piessevaux H, Borovicka J, Mion F, Fox M, Bredenoord AJ, Louis H, Dedrie S, Hoppenbrouwers M, Meulemans A, Rykx A, Thielemans L, Ruth M. Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment. Neurogastroenterol Motil 2015;27:258-68. [PMID: 25530111 DOI: 10.1111/nmo.12484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]